Characteristics of patients with a favorable natural course of myopic choroidal neovascularization

Hayashi, Kengo; Ohno‐Matsui, Kyoko; Yoshida, Takeshi; Kobayashi, Kanako; Kojima, Ariko; Shimada, Noriaki; Yasuzumi, Kenjiro; Futagami, Soh; Tokoro, Takashi; Mochizuki, Manabu

doi:10.1007/s00417-004-0960-5

Cited by 61 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the patients' age has been shown to have influence on natural history and visual outcome after treatment of mCNVs, 24,[29][30][31][32] it was not significantly associated with visual outcome after IVB treatment in our eyes. The reason might be that most of the patients in this study were older with a mean age of 65.1±10.2 years, and 20 of the 23 patients (87.0%) were over 60 years of age.…”

Section: Discussionmentioning

confidence: 47%

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

Nakanishi

Tsujikawa

Yodoi

et al. 2011

Eye

View full text Add to dashboard Cite

Purpose To determine the pre-treatment ocular factors significantly associated with the visual outcome 24 months after intravitreal bevacizumab (IVB) for myopic choroidal neovascularization (mCNV). Methods A total of 23 eyes of 23 patients with mCNV were treated with IVB followed by as needed therapy. The efficacy of IVB was evaluated by the best-corrected visual acuity (BCVA) at 24 months after the initial treatment. Forward stepwise multiple linear regression analyses were performed to evaluate the influence of pre-treatment factors on the BCVA and the improvement of the BCVA at 24 months. Results The mean pre-IVB BCVA was 0.74±0.30 logarithm of the minimum angle of resolution (logMAR) units, and it improved to 0.43±0.31 logMAR units after 1 month (Po0.001, paired t-test). The improvement was maintained at 24 months (0.46 ± 0.40, Po0.005). The mean number of IVB performed during the 24 months was 1.35 ± 0.71. Forward stepwise regression analysis showed that the pre-IVB CNV size (standardized b ¼ 0.52, Po0.01) and BCVA (standardized b ¼ À0.44, Po0.05) significantly affected the visual acuity change after 24 months. The CNV size was the only factor that significantly affected the BCVA after 24 months (standardized b ¼ 0.56, Po0.01). Conclusions IVB with as needed therapy for mCNV led to a rapid and sustained visual improvement. Smaller CNV size was a significant prognostic factor that predicts better visual acuity. Patients with lower pre-treatment BCVA had better visual recovery than those with better pre-treatment BCVA, however, this may be due to a ceiling/floor effect.

show abstract

Section: Discussionmentioning

confidence: 47%

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

Nakanishi

Tsujikawa

Yodoi

et al. 2011

Eye

View full text Add to dashboard Cite

show abstract

“…Hayashi et al [85] studied prospectively 57 eyes with myopic CNV during a minimum follow-up of 5 years after the onset of CNV. Only 14% had a visual acuity better than 20/40 in the final visit compared with 65% of the eyes with a final visual acuity worse than 20/200.…”

Section: Cnv In Pathological Myopiamentioning

confidence: 99%

Myopic Maculopathy: A Review

Silva

2012

Ophthalmologica

105

View full text Add to dashboard Cite

Pathological myopia is a major cause of irreversible vision loss and is the fourth to ninth most frequent cause of blindness in the world. Choroidal neovascularization (CNV) secondary to pathological myopia is the leading cause of vision impairment in patients younger than 50 years. New scientific contributions have been made to the understanding of high myopia and associated CNV. New treatments have been used in recent years, and the results are still controversial. This paper is an updated review of pathological myopia – its definition and progression, epidemiology and genetics – and a review of myopic CNV including the natural history, epidemiology, risk factors, pathogenic mechanisms and treatment.

show abstract

“…4,13,43 No nosso estudo 69 dos 84 olhos (81,1%) apresentavam lesão subfoveal. No entanto, a localização da lesão não influenciou significativamente a MAVC ou a EF (p = 0,2 e p = 0,8, respetivamente).…”

Section: Discussionunclassified

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

et al. 2014

View full text Add to dashboard Cite

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes. Material and Methods:In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment. Results:The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9µm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001). Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

show abstract

Characteristics of patients with a favorable natural course of myopic choroidal neovascularization

Abstract: Some young patients with myopic CNV retain favorable vision over the long term without active treatment. These information might be useful to predict the visual outcome of patients with myopic CNV.

Cited by 61 publications

References 18 publications

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

Myopic Maculopathy: A Review

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

Contact Info

Product

Resources

About